Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis

Reny, Jean-Luc; De Moerloose, Philippe; Dauzat, M.; Fontana, Pierre

doi:10.1111/j.1538-7836.2008.02897.x

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis
Authors		Reny, Jean-Luc De Moerloose, Philippe Dauzat, M. Fontana, Pierre
Published in		Journal of Thrombosis and Haemostasis. 2008, vol. 6, no. 3, p. 444-50
Abstract		BACKGROUND: PFA-100 is a point-of-care assay that evaluates platelet reactivity in high-shear-stress conditions by measuring the closure time (CT) of a membrane aperture. When determined with a collagen/epinephrine cartridge (CEPI), the CT is usually prolonged by aspirin. Studies of the predictive value of a short PFA-100CT(CEPI) for ischemic events in aspirin-treated patients have given variable results. OBJECTIVES: To conduct a systematic review and meta-analysis of studies on the clinical predictive value of a short PFA-100CT(CEPI) in aspirin-treated cardiovascular patients. PATIENTS AND METHODS: Relevant studies were identified by scanning electronic databases. Studies were selected if they included aspirin-treated patients with symptomatic atherosclerosis, measured the PFA-100CT(CEPI), used a CT cut-off value to define aspirin 'responders' and 'non-responders', and reported ischemic events. RESULTS: We selected seven non-prospective studies (1466 patients) and eight prospective studies (1227 patients). In non-prospective studies, the PFA-100CT(CEPI) was performed after the ischemic clinical endpoint, and a publication bias was identified. In prospective studies, the global odds ratio (OR) for the recurrence of an ischemic event in 'aspirin non-responders' relative to 'aspirin responders' was 2.1 [95% confidence interval (CI) 1.4-3.4, P < 0.001]. Pooled analysis with a random effect model revealed no heterogeneity (Q Cochran P = 0.36 and I(2) = 9.4%). CONCLUSIONS: A short PFA-100CT(CEPI) is associated with increased recurrence of ischemic events in aspirin-treated cardiovascular patients. This finding needs to be confirmed in stable ischemic patients, and the PFA-100CT(CEPI) cut-off needs to be refined in these patients.
Keywords		Anti-Inflammatory Agents, Non-Steroidal/pharmacology — Aspirin/pharmacology — Blood Platelets/cytology — Cardiology/methods — Clinical Trials as Topic — Humans — Myocardial Ischemia — Platelet Activation — Platelet Aggregation — Platelet Aggregation Inhibitors/pharmacology — Predictive Value of Tests — Prospective Studies — Time Factors
Identifiers		DOI: 10.1111/j.1538-7836.2008.02897.x PMID: 18194417
Full text		Article (Accepted version) (188 Kb) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine
Research groups		Anticorps antiphospholipides (12) Geneva Platelet Group (13)
Citation (ISO format)		RENY, Jean-Luc et al. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. In: Journal of Thrombosis and Haemostasis, 2008, vol. 6, n° 3, p. 444-50. doi: 10.1111/j.1538-7836.2008.02897.x https://archive-ouverte.unige.ch/unige:1937